Sanofi’s Post

🤲 🌏 Sanofi Consumer Healthcare beweist soziale und ökologische Verantwortung! Genau dafür wurde Westeuropa jetzt mit der B Corp-Zertifizierung ausgezeichnet – weitere Länder folgen: Sanofi Consumer Healthcare’s B Corp Journey. https://bit.ly/3VdK3I9

How can #AI help improve diversity within clinical operations without bias? 🤝 We know that fairness, diversity, and equity in AI development is key to a future where #healthcare is truly inclusive and accessible to all. @LionelBascles, our Head of Clinical Sciences & Operations, explains how our teams are working towards this goal. ⬇️ Learn more about our Responsible AI approach: http://spkl.io/604247nDw

We have been named No. 7 and 1 in the Pharma Industry on TIME's list of the World's 500 Most Sustainable Companies! Our work on environmental sustainability and resilience matters deeply to us. We work hard at being good to our planet, and our dedication to improving people’s lives goes beyond innovations in healthcare. Learn how we’re minimizing the environmental impacts of our products and activities ➡️ http://spkl.io/604147b5d #Sustainability

The European Commission has approved our treatment for adults with uncontrolled chronic obstructive pulmonary disease (#COPD). This first-ever targeted therapy for adults with COPD is also the first new treatment approach for the disease in more than a decade. Read more about the news: https://lnkd.in/epA-WbdW CC: Regeneron

Our commitment to AI is integrated across our entire drug development process. One of the most exciting examples is the development and leveraging of virtual patient populations, more commonly (and fondly) known as “digital twins.” Sanofi’s Global Head of Translational Disease Modeling Thomas Klabunde explains how digital “twinning” works and how it is helping accelerate the R&D process across asthma and other immune-mediated diseases. Read more: http://spkl.io/6040471ZA

Ever wonder what it's like to be an official #Torchbearer for the Paris 2024 Olympic Torch Relay? We captured some of the most exclusive and exciting moments from behind the scenes with #Paris2024, when the #Olympic Flame Paris 2024 stopped by our site in Neuville-sur-Saône, France 🙌

The New England Journal of Medicine (NEJM Group) has published positive Phase 3 results regarding our medicine in children aged 1 to 11 years with eosinophilic esophagitis (#EoE). Read more about how we are working with Regeneron to change the standard of care for young children living with the disease. Read our press release: http://spkl.io/604447BBQ

Only 1 month to go to the Olympic and Paralympic Games Paris 2024 🔥 Over the past few months, we have shared the inspiring stories of our #TeamSanofi athletes and Sanofians. We want to thank our family, friends, and mentors who inspire us in our pursuit of what’s next – whether in sports or in science. Here is to the people who taught us to never settle. #WeNeverSettle #IgnitingPotential Paris 2024 - Comité d'organisation des Jeux Olympiques et Paralympiques de 2024

We see a future where #mRNA can revolutionize #vaccines and treat genetic diseases. But what does it look like? 🧬 Neha Kaushal chatted with Daniel Anderson, Professor of Chemical Engineering at MIT, about the potential of mRNA therapies and the importance of the drug delivery technologies behind them. 🎥 Check out the full video to learn more about our collaboration! 👉 http://spkl.io/60484A2vO